Stocks and Investing Stocks and Investing
Mon, July 3, 2023
Fri, June 30, 2023

Geulah Livshits Reiterated (TSHA) at Strong Buy and Held Target at $5 on, Jun 30th, 2023


Published on 2024-10-28 04:36:50 - WOPRAI, Geulah Livshits
  Print publication without navigation


Geulah Livshits of Chardan Capital, Reiterated "Taysha Gene Therapies, Inc." (TSHA) at Strong Buy and Held Target at $5 on, Jun 30th, 2023.

Geulah has made no other calls on TSHA in the last 4 months.



There are 5 other peers that have a rating on TSHA. Out of the 5 peers that are also analyzing TSHA, 1 agrees with Geulah's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Michael Lapides of "Morgan Stanley" Maintained at Hold with Decreased Target to $1 on, Thursday, March 30th, 2023


These are the ratings of the 4 analyists that currently disagree with Geulah


  • Gil Blum of "Needham" Reiterated at Strong Buy and Held Target at $6 on, Thursday, June 29th, 2023
  • Joon Lee of "Truist Securities" Maintained at Strong Buy with Decreased Target to $2 on, Monday, May 15th, 2023
  • Kristen Kluska of "Cantor Fitzgerald" Maintained at Buy with Decreased Target to $2 on, Thursday, March 30th, 2023
  • Silvan Tuerkcan of "JMP Securities" Reiterated at Buy and Held Target at $4 on, Thursday, March 30th, 2023
Contributing Sources